Bova G S, Carter B S, Bussemakers M J, Emi M, Fujiwara Y, Kyprianou N, Jacobs S C, Robinson J C, Epstein J I, Walsh P C
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
Cancer Res. 1993 Sep 1;53(17):3869-73.
Allelic loss studies have been instrumental in identifying tumor suppressor gene loci in a variety of cancers. In this study we analyzed prostate cancer specimens from 52 patients for allelic loss using 8 polymorphic probes for the short arm of chromosome 8. Overall, 32 of 51 (63%) informative tumors showed loss of at least one locus on chromosome 8p. The most frequently deleted region is observed at chromosome 8p22-8p21.2. Loss of one allele is identified in 14 of 23 (61%) tumors at D8S163, in 15 of 32 (47%) tumors at lipoprotein lipase, and in 20 of 29 (69%) tumors at MSR, all on 8p22. Loss of one allele is identified in 16 of 27 (59%) tumors at D8S220 at 8p21.3-8p21.2. In addition to frequent loss of one allele at the MSR locus, one metastatic prostate cancer sample demonstrated homozygous deletion of MSR sequences. Loci telomeric and centromeric to this region are largely retained. A chromosome 8p deletion map is constructed and defines the smallest region of overlap to a 14-cM interval at 8p22 between D8S163 and lipoprotein lipase, flanking the MSR locus. Evidence of chromosome 8q multiplication at locus D8S39 was detected in 5 of 32 (16%) tumors, all of which demonstrated loss with at least one probe on chromosome 8p. This study extends the previous finding of frequent loss of chromosome 8p in prostate cancer by defining a common region of loss of heterozygosity at 8p22 and a homozygous deletion of the MSR locus contained within this region. This is the first homozygous deletion identified in the genome of a human prostate cancer and the highest rate of loss yet reported on chromosome 8p in cancer. These results strongly suggest the presence of a tumor suppressor gene in this region which is frequently inactivated in prostate cancer.
等位基因缺失研究对于在多种癌症中识别肿瘤抑制基因位点起到了重要作用。在本研究中,我们使用针对8号染色体短臂的8个多态性探针,分析了52例患者的前列腺癌标本中的等位基因缺失情况。总体而言,51例(63%)信息充分的肿瘤中有32例显示8号染色体短臂上至少有一个位点缺失。最常缺失的区域位于8号染色体短臂22区至21.2区。在位于8号染色体短臂22区的D8S163位点,23例肿瘤中有14例(61%)检测到一个等位基因缺失;在脂蛋白脂肪酶位点,32例肿瘤中有15例(47%)检测到一个等位基因缺失;在MSR位点,29例肿瘤中有20例(69%)检测到一个等位基因缺失。在位于8号染色体短臂21.3区至21.2区的D8S220位点,27例肿瘤中有16例(59%)检测到一个等位基因缺失。除了MSR位点经常出现一个等位基因缺失外,一份转移性前列腺癌样本显示MSR序列纯合缺失。该区域端粒和着丝粒方向的位点大多保留。构建了8号染色体短臂缺失图谱,确定了D8S163和脂蛋白脂肪酶之间8号染色体短臂22区一个14厘摩区间的最小重叠区域,该区域以MSR位点为侧翼。在32例肿瘤中有5例(16%)在D8S39位点检测到8号染色体长臂倍增的证据,所有这些肿瘤在8号染色体短臂上至少有一个探针检测到缺失。本研究通过确定8号染色体短臂22区杂合性缺失的共同区域以及该区域内MSR位点的纯合缺失,扩展了先前关于前列腺癌中8号染色体短臂频繁缺失的发现。这是在人类前列腺癌基因组中首次发现的纯合缺失,也是癌症中8号染色体短臂报道的最高缺失率。这些结果强烈表明该区域存在一个肿瘤抑制基因,其在前列腺癌中经常失活。